Evan Wang: Great. And then in terms of some of the pre-commercial manufacturing ramp, can you provide us any color in terms of some estimates or how extensively you plan to build that inventory? And I have two more follow-ups.
Dave Hering: Yes. So on the inventory side, we’ve begun to prepare and have a variety of commercial material at risk, but we continue to balances both making sure that we’re being as cost effective as we can with the cash in our balance sheet, but also making sure that we have doses available. What we’re really looking to do is use a gated approach. So as we move forward, continuing to ramp that up as we start to see data or get to a point of a potential EUA submission and/or the launch. We have a great partner in WuXi, and we continue to look at ways that we can really optimize when those doses would be available and how we commit to them. So that’s really the plan and approach now is start to prime the pump and have some of those doses available for a potential launch and then continue to add to that as we see more information and track further in the process.
Evan Wang: Got it. And in terms of some of the Phase 1 data, I think you guys are tracking that over time. So just wondering how the connects are looking over there, and if there’s any implications or kind of thoughts on, I guess, how redosing could look in the future?
Dave Hering: Pete, do you want to take that one?
Peter Schmidt: Yes. No recent updates from the Phase 1 data. We’ll look at the totality of data coming out of that study and of course, CANOPY to make our conclusions and recommendations about redosing.
Evan Wang: Got it. And last one for me. Great to see all the market research. Just wondering how, I guess, payers and KOLs are looking at, how much did they value clinical data versus the surrogate, is there kind of acceptance of this surrogate beyond FDA?
Dave Hering: Jeremy, do you want to look at that one?
Jeremy Gowler: Yes. I think it’s a good question. For mAb, it certainly is a new concept, but it’s not a new concept in infectious disease with vaccines using surrogate endpoints. So we believe that there will be acceptability of this data beyond just FDA with practitioners and payers.
Operator: Thank you. I’d like to turn the conference back to Dave for closing remarks.
Dave Hering: Thank you all for joining the call today. This is a very exciting time for Invivyd as we approach a potential EUA submission and authorization of VYD222 for the prevention of symptomatic COVID-19, which would represent a significant achievement for Invivyd. But more importantly, it would be a major advancement for the immunocompromised people we serve. We thank you for your continued support and interest in Invivyd, and we look forward to sharing additional updates with you soon. Thank you very much, and have a good evening.
Operator: And this concludes today’s conference call. Thank you for participating. You may now disconnect. Everyone, have a great day.
